


Total spent by companies on promoting key GLP-1 drugs to doctors


OZEMPIC



WEGOVY



ZEPBOUND



MOUNJARO



Source: U.S. Centers for Medicare & Medicaid Services

LYDIA SIDHOM / THE WASHINGTON POST